dr. gafita on prognostic models for treatment with 177lu-psma-617 in mcrpc
Published 4 years ago • 161 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
2:13
dr. gafita on the opportunity for 177lu-psma-617 in mcrpc
-
1:50
dr. gafita on sequencing 177lu-psma-617 in mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
3:01
preliminary findings in mcrpc for fractionated dose 177lu-psma-617
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
3:17
safety and efficacy of 177lu-psma-617
-
21:52
prostate cancer: what's my prognosis? | grade, stage, psa, gleason score and novel genomic assays
-
15:35
lu-psma radioligand therapy
-
5:25
fernando acosta's testimonial with lutetium-177 psma radioligand therapy.
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
2:16
testing the validity of a prognostic model for castration-resistant prostate cancer
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc
-
1:37
recent advances in mhspc: 177lu-psma-617, propel and biomarker-directed strategies
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
2:04
dr. kearns discusses psa genetic correction in prostate cancer
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
6:30
what to know about psa